Year in Review: Dr. P Seo Novel RA therapy on the horizon: ⭐️Peresolimab ➡️ stimulates PD1 ➡️ Phase II, 98 pts ➡️ tx-resistant to other therapies including biologics ➡️ Wk 12: better DAS28, ACR20, not ACR 50/70 #ACR23 @RheumNow

A possible curative therapy of an autoimmune disease via selective depletion of a TRBV-defined group of T cells. This could be potentially applicable to other HLA-B*27-associated spondyloarthropathies. Year in review, Seo #ACR23 @RheumNow https://t.co/NxxkpJhweH. https://t.co/41Po5CHid3

YR in Review: Dr. Seo 🚩GLORIA Trial RA pts > 65yo: prednisolone 5 mg/d x 2 yrs vs PBO + std care ➡️decr dz activity (DAS ⬇️0.37) but 24% incr ADE 🚩Extension: ➡️Tapered off pred over 3m and.. ⭐️NO ADRENAL INSUFF But, small incr in dz activity (DAS ⬆️0.23) #ACR23 @RheumNow https://t.co/YQbS6C8ZT5

#ACR23 Memorable Quote as reminded to us by Dr. P Seo during Year in Review: "What you think of as a rare manifestation of a common disease is probably a common presentation of a disease you are not aware of (yet)!" - Prof Seza Zen, MD @RheumNow https://t.co/Xhwb1brLKG

Yet another (mostly) reassuring report about lymphoma and DMARDS The skin cancer signal in the CIRT trial was weird; would be worth looking into that in observational studies as well @NamrataRheum #ACR23 Abst0438 @RheumNow https://t.co/Beg8UUe2mn

It seems so simple. We should be able to use proteomics to better pick winners when it comes to b/tsDMARDs in RA. Why is it hard? I guess: - theory ≠ practice - too many other factors - it's too easy not to Yet I hope/believe, one day we'll do better. #ACR23 ABST0427 @RheumNow https://t.co/5VBVp3KOJN

If you're >65 years old & have new RA, you start a DMARD, right? At worst, sometime in the first year? US Medicare data 2008-17 n=33,373 only 30% have a DMARD on file (of which bDMARD <10%) >5% on PNL alone Do we hate old people with RA?😔 @JihaRheum #ACR23 ABST0433 @RheumNow https://t.co/1CUXAh3fi0

Revisiting question in #painful #knee #osteoarthritis Which #steroid to inject - esp with #triamcinolone #hexacetonide shortages which is superior to #acetonide. New extended release #fluticasome #propionate > #placebo ? Is how about vs IA steroids LB04 @RheumNow @ACRheum #ACR23 https://t.co/qJazwihSe0

Kudos @AlexisOgdie & co for their work in this area Given proliferation of database research for causal inference, super important to have validated criteria to identify diseases Many spaces (looking at you sarcoidosis) where this is almost entirely absent @RheumNow #ACR23 https://t.co/krkgWAhjMr

#obesity is a significant RF for #osteoarthritis Assoc'd with: 💠impairment of gut biota 💠microbial translocation Leads to innate immune activation #ACR23 @RheumNow @rheumarhyme https://t.co/iuEvBh3A1j

I underestimated how much joy not-bankrupting our healthcare system would bring me ADA & RTX biosimilars have been wonderful; excited for IL6's to join the party @RheumNow #ACR23 Abstr0445 https://t.co/HGwi37rZpd

Which to use in #EGPA? #Mepolizumab IL5i vs Benralizumab = monoclonal Ab binding to IL5Ralpha. Noninferiority RCT - both are similar. Is more Impt ? IL5 drug vs #Rituximab or #Cyclo for severe Eosinoph granuloma todos w polyangiitis 🤷 #ACR23 ⁦@RheumNow⁩ ⁦@ACRheum⁩ https://t.co/zyZeHHSsck

Contributing Factors for Difficult-to-Treat RA using Natural Language Processing (NLP): joint erosions (OR 2.97 CI95% [2.17; 4.08], p< 0.001) , higher disease activity (median DAS28 3.16 vs 2.89) associated with D2T, Bergier Abst#0383 #ACR23 @RheumNow https://t.co/KARxoa2Z7H

COVID boosters in RA patients: getting the job done (versus healthy controls, irrespective of non-withheld DMARDs excluding ritux) @UChicagoMed #ACR23 ABST0416 @RheumNow https://t.co/HVRjC4dauw

I’m not TYK’ed! Another TYK2 #TAK-279 in #PsA RCT. Yup it works in ballpark of other PsA #Rx. #PASI75 45.7%. No obvious dose response w 15 and 30 mg daily but more #acne at higher dose. #ACR23 @ACRheum @RheumNow poster L12 Where to use vs #Deucravitinib? Too early to say as Ph2 https://t.co/nMkgOlUf6s